Inhibitory effect of hydrogen sulfide on platelet aggregation and the underlying mechanisms

Journal of Cardiovascular Pharmacology

Volumn 64, Issue 5, 2014, Pages 481-487

  Zhong, Lingling ^a   Lv, Lei ^a   Yang, Jiayin ^a   Liao, Xiaohong ^a   Yu, Jiangang ^a   Wang, Rui ^a,b   Zhou, Ping ^a  

^a FUDAN UNIVERSITY   (China)

^b LAKEHEAD UNIVERSITY   (Canada)

Author keywords

Calcium signaling; Collagen; Hydrogen sulfide; Ox ldl; Platelets

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM; COLLAGEN; HYDROGEN SULFIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN E; LIPID;

ANIMAL EXPERIMENT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CALCIUM CELL LEVEL; CALCIUM SIGNALING; DYSLIPIDEMIA; FEMALE; HUMAN; IN VITRO STUDY; KNOCKOUT MOUSE; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; MEASUREMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION; THROMBOSIS; ADULT; ANIMAL; BLOOD; DRUG EFFECTS; GENETICS; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; ADULT; ANIMALS; APOLIPOPROTEINS E; CALCIUM; COLLAGEN; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROGEN SULFIDE; IN VITRO TECHNIQUES; LIPID METABOLISM; LIPIDS; MALE; MICE; MICE, KNOCKOUT; PHOSPHORYLATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84927731202     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000142     Document Type: Article

References (41)

1. Wang R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol Rev. 2012;92:791-896.
2. Ali MY, Ping CY, Mok YY, et al. Regulation of vascular nitric oxide in vitro and in vivo; a new role for endogenous hydrogen sulphide? Br J Pharmacol. 2006;149:625-634.
3. Cheng Y, Ndisang JF, Tang G, et al. Hydrogen sulfide-induced relaxation of resistance mesenteric artery beds of rats. Am J Physiol Heart Circ Physiol. 2004;287:H2316-H2323.
4. Yang G, Wu L, Jiang B, et al. H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science. 2008;322:587-590.
5. Zhao W, Wang R. H(2)S-induced vasorelaxation and underlying cellular and molecular mechanisms. Am J Physiol Heart Circ Physiol. 2002;283: H474-H480.
6. Whiteman M, Gooding KM, Whatmore JL, et al. Adiposity is a major determinant of plasma levels of the novel vasodilator hydrogen sulphide. Diabetologia. 2010;53:1722-1726.
7. Wang R. Is H2S a stinky remedy for atherosclerosis? Arteriosclerosis Thromb Vasc Biol. 2009;29:156-157.
8. Wang Y, Zhao X, Jin H, et al. Role of hydrogen sulfide in the development of atherosclerotic lesions in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2009;29:173-179.
9. Chang L, Geng B, Yu F, et al. Hydrogen sulfide inhibits myocardial injury induced by homocysteine in rats. Amino Acids. 2008;34:573-585.
10. Muzaffar S, Shukla N, Bond M, et al. Exogenous hydrogen sulfide inhibits superoxide formation, NOX-1 expression and Rac1 activity in human vascular smooth muscle cells. J Vasc Res. 2008;45:521-528.
11. Laggner H, Muellner MK, Schreier S, et al. Hydrogen sulphide: a novel physiological inhibitor of LDL atherogenic modification by HOCl. Free Radic Res. 2007;41:741-747.
12. Meng QH, Yang G, Yang W, et al. Protective effect of hydrogen sulfide on balloon injury-induced neointima hyperplasia in rat carotid arteries. Am J Pathol. 2007;170:1406-1414.
13. Furie B, Furie BC, Flaumenhaft R. A journey with platelet P-selectin: The molecular basis of granule secretion, signalling and cell adhesion. Thromb Haemost. 2001;86:214-221.
14. Furie B. Pathogenesis of thrombosis. Hematology Am Soc Hematol Educ Program. 2009:255-258.
15. Schulz C, Penz S, Hoffmann C, et al. Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo. Basic Res Cardiol. 2008;103:356-367.
16. Zagli G, Patacchini R, Trevisani M, et al. Hydrogen sulfide inhibits human platelet aggregation. Eur J Pharmacol. 2007;559:65-68.
17. Shankar H, Murugappan S, Kim S, et al. Role of G protein-gated inwardly rectifying potassium channels in P2Y12 receptor-mediated platelet functional responses. Blood. 2004;104:1335-1343.
18. Ding Z, Bynagari YS, Mada SR, et al. Studies on the role of the extracellular cysteines and oligomeric structures of the P2Y12 receptor when interacting with antagonists. J Thromb Haemost. 2009;7:232-234.
19. Zhang S, Hu L, Du H, et al. BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism. Thromb Haemost. 2010;104:845-857.
20. Chang MC, Wang TM, Yeung SY, et al. Antiplatelet effect by p-cresol, a uremic and environmental toxicant, is related to inhibition of reactive oxygen species, ERK/p38 signaling and thromboxane A2 production. Atherosclerosis. 2011;219:559-565.
21. Liu J, Pestina TI, Berndt MC, et al. The roles of ADP and TXA in botrocetin/VWF-induced aggregation of washed platelets. J Thromb Haemost. 2004;2:2213-2222.
22. Allison GL, Lowe GM, Rahman K. Aged garlic extract may inhibit aggregation in human platelets by suppressing calcium mobilization. J Nutr. 2006;136(suppl 3):789S-792S.
23. Liu FC, Liao CH, Chang YW, et al. Splitomicin suppresses human platelet aggregation via inhibition of cyclic AMP phosphodiesterase and intracellular Ca++ release. Thromb Res. 2009;124:199-207.
24. Surin WR, Barthwal MK, Dikshit M. Platelet collagen receptors, signaling and antagonism: emerging approaches for the prevention of intravascular thrombosis. Thromb Res. 2008;122:786-803.
25. Hirabayashi T, Murayama T, Shimizu T. Regulatory mechanism and physiological role of cytosolic phospholipase A2. Biol Pharm Bull. 2004;27:1168-1173.
26. Dogne JM, Hanson J, Pratico D. Thromboxane, prostacyclin and isoprostanes: Therapeutic targets in atherogenesis. Trends Pharmacol Sci. 2005; 26:639-644.
27. Varga-Szabo D, Braun A, Nieswandt B. Calcium signaling in platelets. J thromb haemost. 2009;7:1057-1066.
28. Harper MT, Poole AW. Store-operated calcium entry and noncapacitative calcium entry have distinct roles in thrombin-induced calcium signalling in human platelets. Cell Calcium. 2011;50:351-358.
29. Bird GS, Aziz O, Lievremont JP, et al. Mechanisms of phospholipase C-regulated calcium entry. Curr Mol Med. 2004;4:291-301.
30. Nieswandt B, Brakebusch C, Bergmeier W, et al. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. EMBO J. 2001;20:2120-2130.
31. Oury C, Toth-Zsamboki E, Thys C, et al. The ATP-gated P2X1 ion channel acts as a positive regulator of platelet responses to collagen. Thromb Haemost. 2001;86:1264-1271.
32. Nakamura F, Minshall RD, Le Breton GC, et al. Thromboxane A2 mediates the stimulation of inositol 1, 4, 5-trisphosphate production and intracellular calcium mobilization by bradykinin in neonatal rat ventricular cardiomyocytes. Hypertension. 1996;28:444-449.
33. Vezza R, Mezzasoma AM, Venditti G, et al. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets. Thromb Haemost. 2002;87:114-121.
34. Coulon L, Calzada C, Moulin P, et al. Activation of p38 mitogenactivated protein kinase/cytosolic phospholipase A2 cascade in hydroperoxide-stressed platelets. Free Radic Biol Med. 2003;35: 616-625.
35. Bugaud F, Nadal-Wollbold F, Levy-Toledano S, et al. Regulation of c-jun-NH2 terminal kinase and extracellular-signal regulated kinase in human platelets. Blood. 1999;94:3800-3805.
36. Saklatvala J, Rawlinson L, Waller RJ, et al. Role for p38 mitogenactivated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue. J Biol Chem. 1996;271:6586-6589.
37. Hughes PE, Renshaw MW, Pfaff M, et al. Suppression of integrin activation: a novel function of a Ras/Raf-initiated MAP kinase pathway. Cell. 1997;88:521-530.
38. Barry FA, Gibbins JM. Protein kinase B is regulated in platelets by the collagen receptor glycoprotein VI. J Biol Chem. 2002;277:12874-12878.
39. Nagy B Jr, Jin J, Ashby B, et al. Contribution of the P2Y12 receptormediated pathway to platelet hyperreactivity in hypercholesterolemia. J thromb haemost. 2011;9:810-819.
40. Akkerman JW. From low-density lipoprotein to platelet activation. Int J Biochem Cell Biol. 2008;40:2374-2378.
41. Desai KM, Chang T, Untereiner A, et al. Hydrogen sulfide and the metabolic syndrome. Expert Rev Clin Pharmacol. 2011;4:63-73.